# Qing

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 98 papers | 1,800 citations | 318942 23 h-index | 371746 37 g-index |
| 99 all docs | 99 docs citations | 99 times ranked | 2592 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | CNS Neurotoxicity of Antiretrovirals. Journal of NeuroImmune Pharmacology, 2021, 16, 130-143. | 2.1 | 58 |
| 2 | Pharmacokinetic drug interactions of integrase strand transfer inhibitors. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100044. | 1.7 | 13 |
| 3 | Emerging role for pharmacogenomics in HIV research in Africa. Future Virology, 2021, 16, 307-310. | 0.9 | 0 |
| 4 | Patient-reported outcomes for HIV: the future of long-acting injectables and antiretroviral therapy evaluations. Future Virology, 2021, 16, 543-553. | 0.9 | 1 |
| 5 | Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Journal of Infection and Public Health, 2021, 14, 1169-1173. | 1.9 | 0 |
| 6 | Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid. Clinical Infectious Diseases, 2020, 71, 982-988. | 2.9 | 6 |
| 7 | Antiretroviral drug concentrations in brain tissue of adult decedents. Aids, 2020, 34, 1907-1914. | 1.0 | 34 |
| 8 | Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB). Journal of NeuroImmune Pharmacology, 2020, 15, 7-9. | 2.1 | 5 |
| 9 | Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants. Current Topics in Behavioral Neurosciences, 2020, 50, 517-545. | 0.8 | 13 |
| 10 | <p>Plasma brain-derived neurotrophic factor (BDNF) concentration and the <em>BDNF</em> Val66Met polymorphism in suicide: a prospective study in patients with depressive disorder</p>. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 97-106. | 0.4 | 15 |
| 11 | Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients. Expert Review of Clinical Pharmacology, 2019, 12, 565-571. | 1.3 | 0 |
| 12 | Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462. | 2.1 | 15 |
| 13 | A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients. Pharmacotherapy, 2019, 39, 1179-1189. | 1.2 | 7 |
| 14 | B-07 Benzodiazepine Use Is Associated with an Increased Risk for HIV-Associated Neurocognitive Disorders. Archives of Clinical Neuropsychology, 2019, 34, 951-951. | 0.3 | 0 |
| 15 | Mentored postdoctoral training in Zimbabwe: A report on a successful collaborative effort. Journal of Public Health in Africa, 2019, 10, 1081. | 0.2 | 4 |
| 16 | Benzodiazepine Use Is Associated With an Increased Risk of Neurocognitive Impairment in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 475-482. | 0.9 | 13 |
| 17 | Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 1.4 | 12 |
| 18 | Development and validation of an LCâ€“MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 163-169. | 1.4 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Development and validation of a UHPLCâ€“MS/MS assay for elvitegravir measurement in human plasma and cerebrospinal fluid. Separation Science Plus, 2018, 1, 325-333. | 0.3 | 2 |
| 20 | Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy. Aids, 2017, 31, 787-795. | 1.0 | 19 |
| 21 | Aspirin responsiveness changes in obese patients following bariatric surgery. Cardiovascular Therapeutics, 2017, 35, e12268. | 1.1 | 8 |
| 22 | Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Directâ€Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications. Clinical Pharmacology in Drug Development, 2017, 6, 135-139. | 0.8 | 5 |
| 23 | Translational pharmacology and HIV reservoir eradication strategies. Future Virology, 2017, 12, 631-633. | 0.9 | 0 |
| 24 | Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy, 2017, 37, 1073-1080. | 1.2 | 13 |
| 25 | Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naÃ¯ve HIV-infected individuals. Journal of NeuroVirology, 2017, 23, 704-712. | 1.0 | 44 |
| 26 | Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population. Expert Review of Clinical Pharmacology, 2017, 10, 1145-1152. | 1.3 | 3 |
| 27 | Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Therapeutic Drug Monitoring, 2017, 39, 596-603. | 1.0 | 10 |
| 28 | Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. Journal of Infectious Diseases, 2017, 216, 554-564. | 1.9 | 23 |
| 29 | Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals. AIDS Research and Treatment, 2016, 2016, 1-13. | 0.3 | 22 |
| 30 | Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. Journal of NeuroVirology, 2016, 22, 170-178. | 1.0 | 112 |
| 31 | Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Current Vascular Pharmacology, 2016, 14, 280-287. | 0.8 | 8 |
| 32 | Recent advances in management of the HIV/HCV coinfected patient. Future Virology, 2015, 10, 981-997. | 0.9 | 4 |
| 33 | Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection. PLoS ONE, 2015, 10, e0130583. | 1.1 | 19 |
| 34 | Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 1370-1376. | 1.3 | 18 |
| 35 | Interaction of disulfiram with antiretroviral medications: Efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. American Journal on Addictions, 2014, 23, 137-144. | 1.3 | 15 |
| 36 | Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. Journal of Antimicrobial Chemotherapy, 2014, 69, 3300-3310. | 1.3 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Clinical application of the paraspinal erector approach for spinal canal decompression in upper lumber burst fractures. Journal of Orthopaedic Surgery and Research, 2014, 9, 105. | 0.9 | 5 |
| 38 | Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 390-396. | 0.9 | 32 |
| 39 | Single-tablet, once-daily treatment regimens for HIV. Lancet Infectious Diseases, The, 2014, 14, 265-267. | 4.6 | 4 |
| 40 | Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. Clinical Infectious Diseases, 2014, 58, 555-563. | 2.9 | 30 |
| 41 | Determination of Amikacin in Different Pharmaceutical Formulations Using a Resonance Rayleigh Scattering Method with Pontamine Sky Blue. Current Pharmaceutical Analysis, 2014, 10, 105-111. | 0.3 | 5 |
| 42 | Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. Journal of NeuroVirology, 2013, 19, 254-260. | 1.0 | 14 |
| 43 | Comparative Effectiveness of Darunavir 1,200â€‰mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients. AIDS Research and Treatment, 2013, 2013, 1-4. | 0.3 | 1 |
| 44 | Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIVâ€infected Ugandans. HIV Medicine, 2012, 13, 193-201. | 1.0 | 11 |
| 45 | Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Research and Treatment, 2012, 2012, 1-6. | 0.3 | 12 |
| 46 | The Impact of Herbal Drug Use on Adverse Drug Reaction Profiles of Patients on Antiretroviral Therapy in Zimbabwe. AIDS Research and Treatment, 2012, 2012, 1-4. | 0.3 | 18 |
| 47 | Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Research and Treatment, 2012, 2012, 1-3. | 0.3 | 2 |
| 48 | Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir. Clinical Infectious Diseases, 2012, 54, 414-423. | 2.9 | 26 |
| 49 | Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 897, 80-84. | 1.2 | 7 |
| 50 | Pharmacologic approaches to the treatment of Huntington's disease. Movement Disorders, 2012, 27, 31-41. | 2.2 | 73 |
| 51 | Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity in Chinese Patients with HIV Infection. PLoS ONE, 2011, 6, e26739. | 1.1 | 32 |
| 52 | Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related Disorders. Therapeutic Drug Monitoring, 2011, 33, 309-314. | 1.0 | 4 |
| 53 | Drug Interactions in the Treatment and Chemoprophylaxis of Malaria in HIV Infected Individuals in Sub Saharan Africa. Current Drug Metabolism, 2011, 12, 51-56. | 0.7 | 20 |
| 54 | Within-Patient Atazanavir Trough Concentration Monitoring in HIV-1-Infected Patients. Journal of Pharmacy Practice, 2011, 24, 216-222. | 0.5 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Efficacy and safety of pegylated interferon alphaâ€2a therapy for chronic hepatitis C in HIVâ€infected patients with haemophilia. Haemophilia, 2010, 16, 502-507. | 1.0 | 2 |
| 56 | CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients. Therapeutic Drug Monitoring, 2010, 32, 573-578. | 1.0 | 31 |
| 57 | Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 511-514. | 0.9 | 17 |
| 58 | Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir. American Journal on Addictions, 2010, 19, 17-29. | 1.3 | 25 |
| 59 | Lack of Clinically Significant Drug Interactions between Nevirapine and Buprenorphine. American Journal on Addictions, 2010, 19, 30-37. | 1.3 | 24 |
| 60 | Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opinion on Drug Safety, 2010, 9, 743-758. | 1.0 | 28 |
| 61 | Host Proteome Research in HIV Infection. Genomics, Proteomics and Bioinformatics, 2010, 8, 1-9. | 3.0 | 17 |
| 62 | Transcriptomics and Proteomics in the Study of H1N1 2009. Genomics, Proteomics and Bioinformatics, 2010, 8, 139-144. | 3.0 | 19 |
| 63 | Pharmacogenomics ofCYP3A: considerations for HIV treatment. Pharmacogenomics, 2009, 10, 1323-1339. | 0.6 | 46 |
| 64 | Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharmaceutics and Drug Disposition, 2008, 29, 91-101. | 1.1 | 8 |
| 65 | Research in Women and Special Populations. Pharmacotherapy, 2008, 28, 1203-1203. | 1.2 | 3 |
| 66 | Antiretroviral Therapy. Clinical Pharmacokinetics, 2008, 47, 153-172. | 1.6 | 24 |
| 67 | Pharmacogenomics and HIV pharmacotherapy. Expert Review of Clinical Pharmacology, 2008, 1, 5-8. | 1.3 | 0 |
| 68 | Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia. Current Pharmaceutical Design, 2007, 13, 1607-1616. | 0.9 | 31 |
| 69 | Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics, 2007, 8, 227-235. | 0.6 | 36 |
| 70 | Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 197-207. | 1.5 | 14 |
| 71 | Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2007, 29, 560-565. | 1.0 | 15 |
| 72 | Review of HIV-1 Protease Inhibitor Assay Methods. Current Pharmaceutical Analysis, 2007, 3, 180-185. | 0.3 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thrombosis Research, 2007, 119, 653-661. | 0.8 | 20 |
| 74 | Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug and Alcohol Dependence, 2007, 91, 269-278. | 1.6 | 81 |
| 75 | Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics, 2007, 8, 1169-1178. | 0.6 | 3 |
| 76 | Development of oral anticoagulants. British Journal of Clinical Pharmacology, 2007, 64, 263-265. | 1.1 | 11 |
| 77 | Factors Associated with Altered Pharmacokinetics in Substance Users and Nonâ€Substance Users Receiving Lopinavir and Atazanavir. American Journal on Addictions, 2007, 16, 488-494. | 1.3 | 14 |
| 78 | PIII-35Detection of MDR1 single nucleotide polymorphisms in HIV-infected substance users and nonusers. Clinical Pharmacology and Therapeutics, 2006, 79, P67-P67. | 2.3 | 0 |
| 79 | Critical Pathways: The Role of Pharmacy Today and Tomorrow. Pharmacotherapy, 2006, 26, 1358-1368. | 1.2 | 16 |
| 80 | Update on the Pharmacokinetic Aspects of Antiretroviral Agents: Implications in Therapeutic Drug Monitoring. Current Pharmaceutical Design, 2006, 12, 1129-1145. | 0.9 | 14 |
| 81 | Pharmacokinetics and Pharmacodynamics of Enoxaparin in Multiple Trauma Patients. Journal of Trauma, 2005, 59, 1336-1344. | 2.3 | 78 |
| 82 | Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 473-485. | 1.5 | 43 |
| 83 | Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 37-47. | 0.7 | 7 |
| 84 | Molecular and Pharmacologic Profile of Tinzaparin and A Comparable Low-Molecular-Weight Bacterial Sulfaminoheparosan. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 27-37. | 0.7 | 2 |
| 85 | Studies on the Effect of Calcium in Interactions Between Heparin and Heparin Cofactor II Using Surface Plasmon Resonance. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 249-257. | 0.7 | 6 |
| 86 | Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile. Current Pharmaceutical Design, 2004, 10, 983-999. | 0.9 | 47 |
| 87 | Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin. Clinical Pharmacokinetics, 2003, 42, 1043-1057. | 1.6 | 123 |
| 88 | Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. Thrombosis Research, 2003, 112, 249-255. | 0.8 | 5 |
| 89 | Influence of Different Anticoagulant Agents on Fibrinopeptide A Generation. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 273-292. | 0.7 | 3 |
| 90 | Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology. Seminars in Cardiothoracic and Vascular Anesthesia, 2003, 7, 357-377. | 0.4 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 1-17. | 0.7 | 3 |
| 92 | Reference Ranges of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 51-59. | 0.7 | 3 |
| 93 | Reference Intervals of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 115-124. | 0.7 | 12 |
| 94 | Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. Thrombosis Research, 2002, 105, 303-309. | 0.8 | 17 |
| 95 | The bloodâ€“brain barrier accessibility of a heparin-derived oligosaccharides C3. Thrombosis Research, 2002, 105, 447-453. | 0.8 | 55 |
| 96 | Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. Thrombosis Research, 2002, 106, 149-156. | 0.8 | 8 |
| 97 | Inhibition of Tissue Factor-Activated Platelets by Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Receptor Antagonist. Thrombosis Research, 2001, 102, 143-151. | 0.8 | 8 |
| 98 | Global Anticoagulant Effects of a Novel Sulfated Pentomanan Oligosaccharide Mixture. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 149-152. | 0.7 | 6 |